Two multinational drugmakers are teaming up with top global health groups to protect millions of girls in the world’s poorest countries from deadly cervical cancer.
Starting with pilot programs in eight Asian and African nations, the ambitious project ultimately is intended to inoculate more than 30 million girls in more than 40 countries by 2020. Given that most women killed by cervical cancer live in developing countries, the project could have a huge impact.
The endeavor was announced Thursday by the GAVI Alliance, a public-private partnership that’s worked with drugmakers to deliver affordable vaccines to poor countries to treat childhood illnesses that are big killers.
“This is a transformational moment for the health of women and girls across the world,” said Dr. Seth Berkley, CEO of GAVI, which is short for Global Alliance for Vaccines and Immunization.
“A vast gap currently exists between girls in rich and poor countries. With GAVI’s programs we can begin to bridge that gap so that all girls can be protected against cervical cancer no matter where they are born,” he said in a statement.
Drugmakers Merck & Co. and GlaxoSmithKline PLC initially will provide 2.4 million doses of their vaccines against cancer-causing human papilloma virus — for a fraction of the cost commanded in Western countries.
Merck will supply its Gardasil for $4.50 per dose, and Glaxo its Cervarix for $4.60 per dose. In the U.S., the shots cost more than $100 apiece, and a three-dose series over six months is required.
The vaccines protect against the strains of human papilloma virus, or HPV, that most commonly cause cancer. The virus, transmitted during sex, causes cervical cancer as well as vaginal, vulvar, anal and oral cancers. The vaccines prevent roughly 70 percent of those cancers.
In developed countries, older girls and women routinely get Pap tests to check for cervical cancer or signs of precancerous changes in cervical tissue. They’re treated promptly, often before cancer begins, and few die. And increasingly, young girls and now boys as well are vaccinated with either Gardisil or Cervarix, starting as young as age 9, so they’re protected well before they become sexually active.
Not so in poor countries.
“They don’t have the benefit of screening to catch cancer early, when it can still be treated,” Dr. Julie L. Gerberding, president of Merck Vaccines, said in an interview.
As a result, 85 percent of the 275,000 women killed by cervical cancer each year live in poor countries, where HPV is most prevalent.
The GAVI project will begin “demonstration projects” administering the vaccines to girls 9-13, starting in Kenya as early as this month. Then it will be expanded to Ghana, Laos, Madagascar, Malawi, Niger, Sierra Leone and Tanzania.
The goal is for the governments of those countries to show they can set up a national system — with medical staff, clinic supplies, distribution systems and supply management all well organized — to provide the vaccines over the long term. The program also will bring an opportunity to teach the girls about nutrition, sexual health and HIV prevention.
Already, GAVI is planning to provide the shots nationwide in Rwanda, starting next year.
GAVI also will work with the heavy hitters of global health and development groups, including the CDC, the World Health Organization, UNICEF, the Bill & Melinda Gates Foundation and the World Bank. Other partners include the charities, corporations and 18 wealthy countries that help fund GAVi.
About the Author
